Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EGF Theramed Health ( (TSE:TMED) ) has shared an announcement.
EGF Theramed Health Corp. has appointed Lin Ye to its board of directors and named Connor Yuen as interim chief financial officer, following the resignation of former CFO and director Usama Chaudhry. The changes bring leadership with experience in gaming, wagering, interactive technology and property management, which may support EGF’s operational execution and strategic planning as it develops its biomedical online services and medical technology assets.
The company highlighted Ye’s background in operational leadership, strategic planning, market expansion and asset optimization as an asset to its cross-sector growth ambitions. By refreshing its finance and board leadership, EGF appears to be positioning itself to strengthen governance and execution as it works to expand collaborations around its botanical extraction technologies and medical monitoring device platforms.
The most recent analyst rating on (TSE:TMED) stock is a Sell with a C$0.06 price target. To see the full list of analyst forecasts on EGF Theramed Health stock, see the TSE:TMED Stock Forecast page.
Spark’s Take on TSE:TMED Stock
According to Spark, TipRanks’ AI Analyst, TSE:TMED is a Underperform.
The score is driven down primarily by very weak financial performance (no revenue, ongoing losses, negative equity and a thin asset base), compounded by strongly bearish technical momentum (below key moving averages with negative MACD and extremely low RSI). Valuation offers limited support because earnings are negative and no dividend yield is available.
To see Spark’s full report on TSE:TMED stock, click here.
More about EGF Theramed Health
EGF Theramed Health Corp. is a consumer technology company focused on providing biomedical online services for monitoring and treating common health problems. Through its subsidiaries, it holds assets and technologies for extracting and purifying botanical extracts, developing extract formulations, and offering medical monitoring device technology, while pursuing collaborations in medical technology, equipment protocols and laboratory SOPs.
Average Trading Volume: 13,038
Technical Sentiment Signal: Sell
Current Market Cap: C$697K
See more insights into TMED stock on TipRanks’ Stock Analysis page.